Fujian Haixi Pharms Co Ltd

Fujian Haixi Pharmaceuticals Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. Its drugs target oncology, ophthalmology, respiratory, digestive, cardiovascular, endocrine, and nervous system conditions, as well as inflammation, and it also provides pharmaceutical technical services. The company offers generic alternatives including Anbili, Haihuitong, Ruiantuo, Saixifu, Haibiping, Anyoufan, Haikexi, Anfeiping, and Jishuning. Its pipeline includes C019199 for advanced osteosarcoma (phase II completed), HXP056 for retinopathy-related diseases (phase I completed), HXP089 for glioblastoma multiforme, and HXP090 for idiopathic pulmonary fibrosis. Products are sold through retail pharmacies, online pharmacies, and internet medical platforms. Incorporated in 2012, the company is based in Fuzhou, China.